GENMAB

Genmab’s Rina‑S ADC shows 45% ORR and 12‑month DoR in platinum‑resistant ovarian cancer, even low‑FR‑α cases, offering a new, value‑based treatment option.

Genmab’s Phase 1/2 Rina‑S results show a 32% response rate and 13.6‑month median durability in platinum‑resistant ovarian cancer, promising a value‑based breakthrough treatment.

Genmab’s recent filing shows Darwin Global’s voting stake and a brief share price dip, yet the company’s robust oncology pipeline, strong margins and strategic M&A outlook keep long‑term value intact.

Genmab’s share rise signals investor confidence in talquetamab, a bispecific antibody with 77% response and manageable safety, hinting at a new multiple‑myeloma option soon.